CNTB vs. RAPT, ZVRA, KMDA, NBTX, ANL, FBLG, VRCA, STTK, ACIU, and ORGO
Should you be buying Connect Biopharma stock or one of its competitors? The main competitors of Connect Biopharma include RAPT Therapeutics (RAPT), Zevra Therapeutics (ZVRA), Kamada (KMDA), Nanobiotix (NBTX), Adlai Nortye (ANL), FibroBiologics (FBLG), Verrica Pharmaceuticals (VRCA), Shattuck Labs (STTK), AC Immune (ACIU), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical preparations" industry.
Connect Biopharma (NASDAQ:CNTB) and RAPT Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends, community ranking and earnings.
Connect Biopharma has higher earnings, but lower revenue than RAPT Therapeutics.
Connect Biopharma presently has a consensus target price of $6.50, indicating a potential upside of 280.12%. RAPT Therapeutics has a consensus target price of $24.67, indicating a potential upside of 505.32%. Given RAPT Therapeutics' higher probable upside, analysts plainly believe RAPT Therapeutics is more favorable than Connect Biopharma.
Connect Biopharma has a beta of -0.49, meaning that its stock price is 149% less volatile than the S&P 500. Comparatively, RAPT Therapeutics has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500.
Connect Biopharma's return on equity of 0.00% beat RAPT Therapeutics' return on equity.
58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 99.1% of RAPT Therapeutics shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by company insiders. Comparatively, 6.6% of RAPT Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Connect Biopharma and Connect Biopharma both had 4 articles in the media. RAPT Therapeutics' average media sentiment score of 1.19 beat Connect Biopharma's score of 0.55 indicating that RAPT Therapeutics is being referred to more favorably in the news media.
RAPT Therapeutics received 72 more outperform votes than Connect Biopharma when rated by MarketBeat users. However, 69.57% of users gave Connect Biopharma an outperform vote while only 66.17% of users gave RAPT Therapeutics an outperform vote.
Summary
RAPT Therapeutics beats Connect Biopharma on 7 of the 13 factors compared between the two stocks.
Get Connect Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CNTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Connect Biopharma Competitors List
Related Companies and Tools
